Hims & Hers Health (HIMS) Emerges as a Leading Weight Loss Stock Following Barclays' Increased Target
Money

Hims & Hers Health (HIMS) Emerges as a Leading Weight Loss Stock Following Barclays' Increased Target

authorBy JL Collins
DateJun 24, 2026
Read Time2 min

Hims & Hers Health, Inc. (HIMS) is attracting considerable attention in the weight management sector, especially after Barclays significantly uplifted its price target. The financial institution has reiterated its 'Overweight' recommendation for HIMS, boosting the target to $39.00 from its previous $29.00. This positive outlook is underpinned by expectations of robust revenue and EBITDA acceleration in the latter half of 2026, attributed to the company's expanding weight loss solutions and strategic collaborations. Furthermore, HIMS' recent acquisition of Eucalyptus marks a pivotal step in strengthening its global presence and enhancing its digital healthcare offerings.

Barclays' confidence in HIMS stems from various factors, including the expected surge in demand for weight loss treatments. The firm's analysis, as reported on June 17, suggests that HIMS' diversified business segments, coupled with its focus on weight management, will be key drivers of its financial performance. The collaboration with Novo Nordisk is particularly noted for indicating improving market trends and investor confidence in HIMS' future growth trajectory.

Beyond its financial performance, Hims & Hers Health has been strategically expanding its operational footprint. On June 2, the company completed the acquisition of Eucalyptus, a move designed to bolster its global consumer healthcare platform. This acquisition broadens HIMS' access to crucial markets like the United States, the United Kingdom, Australia, and Canada, while also laying the groundwork for further international expansion. By integrating Eucalyptus' digital health expertise and regional capabilities with HIMS' advanced technology platform, the company aims to deliver more tailored and accessible healthcare solutions globally.

Hims & Hers Health, Inc. operates as a prominent telehealth provider, delivering a range of digital healthcare services, including comprehensive weight management programs. Initially offering compounded GLP-1 alternatives, the company has strategically shifted towards branded weight-loss medications through partnerships with leading pharmaceutical firms. This evolution is central to its strategy of building an extensive metabolic health platform, ensuring broad access to effective treatments.

This strategic expansion and positive financial forecasts highlight HIMS' strong position within the competitive healthcare market. The company's proactive approach to partnerships and acquisitions, alongside its commitment to innovative healthcare solutions, positions it favorably for sustained growth and market leadership in the coming years.

More Articles
Money
Elon Musk's Critique of US Tax System and Strategies for Wealth Preservation
Elon Musk recently criticized the American tax system, highlighting that individuals are taxed on earnings, purchases, and ownership. This sparked a discussion on how wealthy individuals often avoid taxable events. This article delves into the strategies for building and preserving wealth through tax-efficient investing, emphasizing long-term approaches, diversification, and the benefits of consulting financial advisors. It also cautions against chasing volatile market trends and illustrates the importance of alternative assets like real estate for a robust portfolio.
By Dave RamseyJun 24, 2026
Money
Industrial Economic Slowdown Impedes Sherwin-Williams' Expansion
Aoris Investment Management's Q1 2026 investor letter highlights the challenges faced by The Sherwin-Williams Company (SHW). The paint and coatings giant experienced weakened growth due to a sluggish industrial economy and reduced property sales, impacting its paint volumes. Despite maintaining market share, concerns arose regarding the structural slowdown in its core markets, prompting Aoris to seek better investment opportunities.
By Chika UwazieJun 24, 2026
Money
BlackRock Endorses Bitcoin Allocation, Signaling Maturation in Institutional Portfolios
BlackRock, the world's largest asset manager, has officially suggested a 1%-2% Bitcoin allocation for investment portfolios. This recommendation, outlined in a research note from its Investment Institute, positions Bitcoin as a valuable diversifier to potentially enhance risk-adjusted returns within traditional investment frameworks. The move underscores Bitcoin's increasing acceptance among institutional investors and could significantly influence wealth management strategies.
By T. Harv EkerJun 24, 2026
Money
Eli Lilly Bolsters Pain Management Portfolio and Advances Cancer Treatment
Eli Lilly recently acquired 4E Therapeutics, a biotech firm specializing in chronic pain therapies, to enhance its neuroscience and pain management research. Concurrently, the company announced positive Phase 3 trial results for Jaypirca, its treatment for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, demonstrating a significant reduction in disease progression or death risk. These strategic moves underscore Eli Lilly's commitment to expanding its therapeutic reach and improving patient outcomes in critical areas.
By Bola SokunbiJun 24, 2026
Money
BP Recognized as a Top UK High-Dividend Stock Amidst Strategic Divestitures
BP (NYSE:BP) has been identified as a leading high-dividend stock in the UK, maintaining a consistent dividend payment record spanning over five decades. The company currently offers a quarterly dividend of $0.4992 per ADS, resulting in an attractive dividend yield of 4.81% as of mid-June. Despite its strong dividend performance, BP is actively pursuing the sale of minority stakes in its Gulf of Mexico projects, aiming to generate billions in capital for future endeavors.
By Natalie PaceJun 24, 2026